So I wrote a little thing for @MolMetab sciencedirect.com/science/articl As we now appreciate, GLP-1 can target multiple brain regions and neuronal populations to reduce food intake, and the clinical results are increasingly impressive #obesity The ongoing SELECT trial will be pivotal for the field sciencedirect.com/science/articl From very modest weight loss with exenatide twice daily, the GLP-1 field has learned, by titration, dose escalation, higher Cmax, and better molecules, to achieve clinically meaningful #weightloss #T2D #obesity More progress to come #obesity described here sciencedirect.com/science/articl Beyond semaglutide and tirzepatide, where might we find the next GLP-1-based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of cagrilintide + semaglutide and make projections out to 52 weeks thelancet.com/journals/lance Join the conversation
These data support future clinical applications using synergistic combinations of metabolites and antibiotics to prevent or mitigate infections with antibiotic-resistant bacterial pathogens
In lab settings the capsules are taken orally 100-500mcg once or twice daily
Moreover, astrocytic modification of excitatory neurotransmitters is mechanistically linked to the dopaminergic system
Peptides for Women : While the dose is the same, women may be more sensitive to the side effects of certain peptides, such as the water retention associated with higher doses of GH-releasing peptides
F.FarasM
